The Role of α1-Microglobulin (A1M) in Erythropoiesis and Erythrocyte Homeostasis-Therapeutic Opportunities in Hemolytic Conditions
(2020) In International Journal of Molecular Sciences 21(19). p.1-21- Abstract
α1-microglobulin (A1M) is a small protein present in vertebrates including humans. It has several physiologically relevant properties, including binding of heme and radicals as well as enzymatic reduction, that are used in the protection of cells and tissue. Research has revealed that A1M can ameliorate heme and ROS-induced injuries in cell cultures, organs, explants and animal models. Recently, it was shown that A1M could reduce hemolysis in vitro, observed with several different types of insults and sources of RBCs. In addition, in a recently published study, it was observed that mice lacking A1M (A1M-KO) developed a macrocytic anemia phenotype. Altogether, this suggests that A1M may have a role in RBC development, stability and... (More)
α1-microglobulin (A1M) is a small protein present in vertebrates including humans. It has several physiologically relevant properties, including binding of heme and radicals as well as enzymatic reduction, that are used in the protection of cells and tissue. Research has revealed that A1M can ameliorate heme and ROS-induced injuries in cell cultures, organs, explants and animal models. Recently, it was shown that A1M could reduce hemolysis in vitro, observed with several different types of insults and sources of RBCs. In addition, in a recently published study, it was observed that mice lacking A1M (A1M-KO) developed a macrocytic anemia phenotype. Altogether, this suggests that A1M may have a role in RBC development, stability and turnover. This opens up the possibility of utilizing A1M for therapeutic purposes in pathological conditions involving erythropoietic and hemolytic abnormalities. Here, we provide an overview of A1M and its potential therapeutic effect in the context of the following erythropoietic and hemolytic conditions: Diamond-Blackfan anemia (DBA), 5q-minus myelodysplastic syndrome (5q-MDS), blood transfusions (including storage), intraventricular hemorrhage (IVH), preeclampsia (PE) and atherosclerosis.
(Less)
- author
- Kristiansson, Amanda LU ; Gram, Magnus LU ; Flygare, Johan LU ; Hansson, Stefan R LU ; Åkerström, Bo LU and Storry, Jill R LU
- organization
-
- Infection Medicine (BMC)
- Antioxidation medicine (research group)
- Division of Hematology and Transfusion Medicine
- Redox Medicine (research group)
- Neonatology (research group)
- LUCC: Lund University Cancer Centre
- Stem Cells to Red Blood Cells (research group)
- Division of Molecular Medicine and Gene Therapy
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Obstetrics and Gynaecology (Lund)
- Transfusion Medicine (research group)
- publishing date
- 2020-09-30
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Molecular Sciences
- volume
- 21
- issue
- 19
- article number
- 7234
- pages
- 1 - 21
- publisher
- MDPI AG
- external identifiers
-
- pmid:33008134
- scopus:85091977851
- ISSN
- 1422-0067
- DOI
- 10.3390/ijms21197234
- language
- English
- LU publication?
- yes
- id
- 759c6dd5-5bf7-442b-8a23-1a280cf3d130
- date added to LUP
- 2020-11-02 12:53:46
- date last changed
- 2024-08-22 05:39:01
@article{759c6dd5-5bf7-442b-8a23-1a280cf3d130, abstract = {{<p>α1-microglobulin (A1M) is a small protein present in vertebrates including humans. It has several physiologically relevant properties, including binding of heme and radicals as well as enzymatic reduction, that are used in the protection of cells and tissue. Research has revealed that A1M can ameliorate heme and ROS-induced injuries in cell cultures, organs, explants and animal models. Recently, it was shown that A1M could reduce hemolysis in vitro, observed with several different types of insults and sources of RBCs. In addition, in a recently published study, it was observed that mice lacking A1M (A1M-KO) developed a macrocytic anemia phenotype. Altogether, this suggests that A1M may have a role in RBC development, stability and turnover. This opens up the possibility of utilizing A1M for therapeutic purposes in pathological conditions involving erythropoietic and hemolytic abnormalities. Here, we provide an overview of A1M and its potential therapeutic effect in the context of the following erythropoietic and hemolytic conditions: Diamond-Blackfan anemia (DBA), 5q-minus myelodysplastic syndrome (5q-MDS), blood transfusions (including storage), intraventricular hemorrhage (IVH), preeclampsia (PE) and atherosclerosis.</p>}}, author = {{Kristiansson, Amanda and Gram, Magnus and Flygare, Johan and Hansson, Stefan R and Åkerström, Bo and Storry, Jill R}}, issn = {{1422-0067}}, language = {{eng}}, month = {{09}}, number = {{19}}, pages = {{1--21}}, publisher = {{MDPI AG}}, series = {{International Journal of Molecular Sciences}}, title = {{The Role of α1-Microglobulin (A1M) in Erythropoiesis and Erythrocyte Homeostasis-Therapeutic Opportunities in Hemolytic Conditions}}, url = {{http://dx.doi.org/10.3390/ijms21197234}}, doi = {{10.3390/ijms21197234}}, volume = {{21}}, year = {{2020}}, }